CLARITY MEDICAL (01406) Reports Revenue of Approximately HK$85 Million for First Half of Fiscal 2026, Down Less Than 3% Year-over-Year

Stock News10-14

CLARITY MEDICAL (01406) announced that for the first half of fiscal year 2026, the group achieved revenue of approximately HK$85 million, representing a slight decline of less than 3% compared to the same period last year. Due to extremely severe weather conditions, the group's Hong Kong clinics were closed or severely disrupted for eight days during July to September. Additionally, negative media coverage resulting from allegations made by a former director may have adversely affected the group's business in recent months. The company has further strengthened its technological leadership in Hong Kong's ophthalmology market through an exclusive partnership with Johnson & Johnson to introduce its next-generation refractive surgery technology, SILK™. This technology employs low-energy, ultra-precise femtosecond laser pulses that effectively reduce corneal tissue damage and nerve damage, thereby achieving faster recovery and better post-operative outcomes. As the first and only institution in Hong Kong to offer SILK™ technology, the company plans to promote this technology in the fourth quarter of 2025.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1147976979?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-14 19:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1147976979","market":"sh","top_or_hot":-1,"title":"CLARITY MEDICAL (01406) Reports Revenue of Approximately HK$85 Million for First Half of Fiscal 2026, Down Less Than 3% Year-over-Year","media":"Stock News","content":"<p>CLARITY MEDICAL (01406) announced that for the first half of fiscal year 2026, the group achieved revenue of approximately HK$85 million, representing a slight decline of less than 3% compared to the same period last year. Due to extremely severe weather conditions, the group's Hong Kong clinics were closed or severely disrupted for eight days during July to September. Additionally, negative media coverage resulting from allegations made by a former director may have adversely affected the group's business in recent months. The company has further strengthened its technological leadership in Hong Kong's ophthalmology market through an exclusive partnership with Johnson & Johnson to introduce its next-generation refractive surgery technology, SILK™. This technology employs low-energy, ultra-precise femtosecond laser pulses that effectively reduce corneal tissue damage and nerve damage, thereby achieving faster recovery and better post-operative outcomes. As the first and only institution in Hong Kong to offer SILK™ technology, the company plans to promote this technology in the fourth quarter of 2025.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CLARITY MEDICAL (01406) Reports Revenue of Approximately HK$85 Million for First Half of Fiscal 2026, Down Less Than 3% Year-over-Year</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCLARITY MEDICAL (01406) Reports Revenue of Approximately HK$85 Million for First Half of Fiscal 2026, Down Less Than 3% Year-over-Year\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-10-14 19:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>CLARITY MEDICAL (01406) announced that for the first half of fiscal year 2026, the group achieved revenue of approximately HK$85 million, representing a slight decline of less than 3% compared to the same period last year. Due to extremely severe weather conditions, the group's Hong Kong clinics were closed or severely disrupted for eight days during July to September. Additionally, negative media coverage resulting from allegations made by a former director may have adversely affected the group's business in recent months. The company has further strengthened its technological leadership in Hong Kong's ophthalmology market through an exclusive partnership with Johnson & Johnson to introduce its next-generation refractive surgery technology, SILK™. This technology employs low-energy, ultra-precise femtosecond laser pulses that effectively reduce corneal tissue damage and nerve damage, thereby achieving faster recovery and better post-operative outcomes. As the first and only institution in Hong Kong to offer SILK™ technology, the company plans to promote this technology in the fourth quarter of 2025.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1219","symbol_name":"保健护理服务","start_time":0,"source_url":"","article_id":"1147976979","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1147976979","pubTimestamp":1760441423,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"CLARITY MEDICAL (01406) announced that for the first half of fiscal year 2026, the group achieved revenue of approximately HK$85 million, representing a slight decline of less than 3% compared to the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1219":"保健护理服务","01406":"清晰医疗"},"translate_title":"CLARITY MEDICAL(01406)公布2026财年上半年营收约8500万港元同比降不到3%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01406":1},"content_text":"CLARITY MEDICAL (01406) announced that for the first half of fiscal year 2026, the group achieved revenue of approximately HK$85 million, representing a slight decline of less than 3% compared to the same period last year. Due to extremely severe weather conditions, the group's Hong Kong clinics were closed or severely disrupted for eight days during July to September. Additionally, negative media coverage resulting from allegations made by a former director may have adversely affected the group's business in recent months. The company has further strengthened its technological leadership in Hong Kong's ophthalmology market through an exclusive partnership with Johnson & Johnson to introduce its next-generation refractive surgery technology, SILK™. This technology employs low-energy, ultra-precise femtosecond laser pulses that effectively reduce corneal tissue damage and nerve damage, thereby achieving faster recovery and better post-operative outcomes. As the first and only institution in Hong Kong to offer SILK™ technology, the company plans to promote this technology in the fourth quarter of 2025.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1147976979","isCrawlerRequest":true}